What is F2G?
F2G operates at the intersection of innovative science and patient-centric healthcare. The company is dedicated to the discovery and development of first-in-class antifungal treatments designed to combat resistant pathogens that pose severe risks to vulnerable patient populations. By prioritizing high-impact research and development, F2G has established a robust market position, attracting top-tier life sciences investors who recognize the urgent need for new therapeutic options in the face of increasing antimicrobial resistance. Their operational model integrates rigorous scientific inquiry with a strategic focus on bringing life-saving medicines from the laboratory to the clinical setting.
How much funding has F2G raised?
F2G has raised a total of $347.9M across 8 funding rounds:
Series A
$6.1M
Private Equity
$9.2M
Other Financing Round
$11.8M
Private Equity
$30M
Series C
$60M
Series D
$60.8M
Unspecified
$70M
Other Financing Round
$100M
Series A (2002): $6.1M, investors not publicly disclosed
Private Equity (2008): $9.2M, investors not publicly disclosed
Other Financing Round (2008): $11.8M supported by BankInvest Biomedical Venture, Astellas Venture Management, K Nominees, and Merifin Capital
Private Equity (2012): $30M featuring Sunstone Capital, Novartis BioVenture Fund, Merifin Capital, Advent Life Sciences, and Astellas Venture Management
Series C (2016): $60M backed by Brace Pharma Capital, Advent Life Sciences, Novo A/S, Aisling Capital, Sectoral Asset Management, Novartis Venture Fund, Merifin Capital, and Sunstone Capital
Series D (2020): $60.8M with participation from Brace Pharma Capital, Advent Life Sciences, Morningside Ventures, Cowen Healthcare Investments, and Novo Holdings
Unspecified (2022): $70M led by Morningside Venture Capital, Advent Life Sciences, Forbion, Sofinnova Partners, Cowen Healthcare Investments, and Novo Holdings
Other Financing Round (2024): $100M supported by The AMR Action Fund, Sofinnova Partners, ICG, Advent Life Sciences, and Novo Holdings
Key Investors in F2G
The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new treatments to combat superbugs.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability with a hands-on approach to company building.
Advent Life Sciences
Advent Life Sciences is a trans-Atlantic venture capital firm focused on building innovative life sciences businesses and developing first-in-class medicines.
What's next for F2G?
Following this major strategic investment, F2G is well-positioned to accelerate its late-stage clinical development programs. The influx of capital will likely be deployed to scale manufacturing capabilities, expand regulatory engagement, and support the commercialization strategy for its lead candidates. As the company transitions into a more mature phase of its lifecycle, the focus will remain on navigating the complex regulatory pathways required to bring transformative antifungal solutions to market. Continued collaboration with its diverse syndicate of venture capital and institutional partners will be instrumental in sustaining the momentum required to address the global burden of fungal disease.
See full F2G company page
